- Home
- USIO vs KPTI Comparison
USIO vs KPTI Comparison
Compare USIO & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- KPTI
- Stock Information
- Founded
- USIO 1998
- KPTI 2008
- Country
- USIO United States
- KPTI United States
- Employees
- USIO N/A
- KPTI N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- KPTI Health Care
- Exchange
- USIO Nasdaq
- KPTI Nasdaq
- Market Cap
- USIO 50.2M
- KPTI 44.5M
- IPO Year
- USIO N/A
- KPTI 2013
- Fundamental
- Price
- USIO $1.46
- KPTI $6.08
- Analyst Decision
- USIO Strong Buy
- KPTI Buy
- Analyst Count
- USIO 1
- KPTI 6
- Target Price
- USIO $4.00
- KPTI $39.80
- AVG Volume (30 Days)
- USIO 75.7K
- KPTI 97.1K
- Earning Date
- USIO 11-05-2025
- KPTI 11-04-2025
- Dividend Yield
- USIO N/A
- KPTI N/A
- EPS Growth
- USIO N/A
- KPTI N/A
- EPS
- USIO 0.11
- KPTI N/A
- Revenue
- USIO $83,851,606.00
- KPTI $137,269,000.00
- Revenue This Year
- USIO $8.66
- KPTI $3.40
- Revenue Next Year
- USIO $13.32
- KPTI $9.69
- P/E Ratio
- USIO $13.74
- KPTI N/A
- Revenue Growth
- USIO 2.05
- KPTI N/A
- 52 Week Low
- USIO $1.24
- KPTI $3.51
- 52 Week High
- USIO $2.92
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- USIO 45.46
- KPTI 49.73
- Support Level
- USIO $1.44
- KPTI $6.15
- Resistance Level
- USIO $1.58
- KPTI $6.85
- Average True Range (ATR)
- USIO 0.07
- KPTI 0.51
- MACD
- USIO 0.01
- KPTI -0.16
- Stochastic Oscillator
- USIO 40.00
- KPTI 16.10
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.